Figure 4

Survival outcomes by stage. Analysis of overall survival according to American Joint Committee on Cancer (AJCC) stages subdivided by NLR revealed a significant worse prognosis for NLR-high subgroups, with a 1.6 fold, 1.5 fold and 2.0 fold risk of death within stages II (HR 1.55, 95% CI 1.10–2.19), III (HR 1.55, 95% CI 1.01–2.37), and IV (HR 2.03, 95% CI 1.14–3.62), respectively.